1. Nivolumab is recommended for patients with squamous lung cancer. After achieving good results with the PD-1 inhibitor Nivolumab (trade name Opdivo) as a second-line drug for melanoma, the company’s researchers made a breakthrough with the drug in a study of advanced squamous lung cancer. It was approved by the FDA on March 4, 2015, for the treatment of metastatic squamous non-small cell lung cancer with disease progression during or after transplatinum-based chemotherapy. Given its efficacy, this guideline adds it as one of the few targeted agents for squamous lung cancer. 2. The threshold for lung nodules was agreed upon in this guideline. The NCCN guidelines state that when a patient is found to have a pulmonary nodule, the patient’s age, smoking history, prior tumor history, family history, occupational exposure, and other lung diseases should first be taken into account. The next step is to take into account the size and density of the nodule on imaging before taking the next step. For pulmonary nodules less than or equal to 8mm or solid nodules less than or equal to 10mm, the NCCN recommends that imaging is sufficient. For solid non-calcified or partially solid nodules larger than 8mm, PET-CT may be considered for definitive diagnosis. If the PET-CT results do not first consider malignancy, a low-dose CT review in 3 months is sufficient; if first considered, a biopsy or surgical resection is needed to make a final diagnosis through pathology. For non-solid nodules larger than 10 mm, a low-dose CT review can be performed in 3-6 months. If the nodule is unchanged, it can be reviewed after 6-12 months, or biopsy or surgical resection and pathology can be performed to clarify the diagnosis; if the nodule increases in size or becomes (partially) solid, surgical resection and pathology are needed to clarify the diagnosis. In addition, NCCN emphasized that for patients with stage I or II lung cancer, surgery can be performed without biopsy. 3. For the first time, the need to assess remission within 1-2 weeks after initial chemotherapy, followed by 2-4 weeks. 4. The evidence level for ramucirumab in combination with docetaxel for the treatment of squamous lung cancer was upgraded from 2B to 2A. Ramucirumab is a vascular endothelial growth factor 2 inhibitor and is considered a successor to the first-generation angiogenesis inhibitor bevacizumab. Although studies have shown a limited effect of ramucirumab in combination with docetaxel for lung cancer, the regimen improves survival independent of lung cancer subtype. This is a welcome relief for squamous lung cancer, which is extremely difficult to treat. 5. Following the downgrading of other cancer nodules presenting in the same lung lobe as the primary tumor from T4 to T3, this update defines them as reaching N1.